Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The MDM2 polymorphism SNP309 is associated with clinical characteristics and outcome in diffuse large B-cell lymphoma.

European journal of haematology - 1 Dec 2014

Hedström Gustav, Thunberg Ulf, Amini Rose-Marie, Zainuddin Norafiza, Enblad Gunilla, Berglund Mattias

Abstract excerpt

INTRODUCTION: The murine double minute 2 (MDM2) gene encodes a regulatory protein of the p53 pathway. A single nucleotide polymorphism (T to G change) at position 309 (SNP309) in the promotor region of MDM2 affects the transcription activity of MDM2 and has been found to be a negative prognostic marker in several cancers. PATIENTS AND METHODS: In this study, the MDM2 SNP309 polymorphism was analysed in 201...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Lymphoma, Large B-Cell, Diffuse

Share to Neoplasm Staging

Share to Prognosis

Share to Proto-Oncogene Proteins c-mdm2

Share to Young Adult

Source

Identifiers

PMID: 24889555
DOI: 10.1111/ejh.12388

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The MDM2 polymorphism SNP309 is associated with clinical characteristics and outcome in diffuse large B-cell lymphoma.PMID 24889555Read ↗

MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.Semantic proximity Read ↗

Prognostic impact of the MDM2SNP309 allele in leukemia and lymphoma.Semantic proximity Read ↗

MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.Semantic proximity Read ↗

Association of MDM2 polymorphism with risk and prognosis of leukemia: a meta-analysis.Semantic proximity Read ↗

Correlations between MDM2 gene SNP309 polymorphism and susceptibility to leukemia.Semantic proximity Read ↗

Significant Association of the MDM2 T309G Polymorphism with Breast Cancer Risk in a Turkish PopulationSemantic proximity Read ↗

Association of breast cancer outcome with status of p53 and MDM2 SNP309.Semantic proximity Read ↗

MDM2 SNP309 variation contributes to leukemia risk: meta-analyses based on 7259 subjects.Semantic proximity Read ↗

MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia.Semantic proximity Read ↗

Individual and combined effects of MDM2 SNP309 and TP53 Arg72Pro on breast cancer risk: an updated meta-analysis.Semantic proximity Read ↗

Role of the MDM2 promoter polymorphism (-309T>G) in acute myeloid leukemia development.Semantic proximity Read ↗

Association between the MDM2 T309G polymorphism and leukemia risk: a meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.